Health Care Facilities

CHAOJU EYE CARE

CHAOJU EYE CARE released FY2025 9 Months Earnings on March 31 (BJT), actual revenue HKD 1.118 B, actual EPS HKD 0.228

CHAOJU EYE CARE released FY2025 Q3 earnings on March 31 (BJT), actual revenue HKD 361.89 M, actual EPS HKD 0.0548

CHAOJU EYE CARE released FY2025 earnings on March 31 During-Market (BJT), actual revenue HKD 1.487 B (forecast HKD 1.626 B), actual EPS HKD 0.2841 (forecast HKD 0.3113)

CHAOJU EYE CARE released FY2025 Q4 earnings on March 31 During-Market (BJT), actual revenue HKD 368.14 M, actual EPS HKD 0.0557

CHAOJU EYE CARE to release FY2025 earnings on March 31, during market hours (BJT), with forecast revenue of HKD 1.595 B and EPS of HKD 0.3076

CHAOJU EYE CARE released FY2025 Q1 earnings on August 29 (BJT), actual revenue HKD 373.91 M, actual EPS HKD 0.0856

CHAOJU EYE CARE released FY2025 Q2 earnings on August 29 After-Market BJT, actual revenue HKD 382.13 M, actual EPS HKD 0.0875

CHAOJU EYE CARE released FY2025 Semi-Annual Earnings on August 29 After-Market (BJT), actual revenue HKD 756.04 M, actual EPS HKD 0.1732

CHAOJU EYE CARE FY2025 Q2 Earnings Release on August 29, 2025 After-Market (BJT)

Choju Eyecare Acquires Ningbo Bosi and Yunshikang to Expand Eyecare Market

Choju Eyecare Appoints Guo Hongyan to Nomination Committee

Choju Eye Care Holdings' Annual General Meeting Resolutions Passed

Choju Eye Holdings Released 2024 Annual Report

Cha Ju Eye Care Holdings Announces 2024 Fiscal Year Results: Revenue Growth but Net Income Decline

Chaoju Eye Care repurchases 16,000 shares for HKD 42,900 on March 27, 2025

Chaoju Eye Hospital Announces 2024 Annual Results with Revenue of 1.405 Billion Yuan, Up 2.62% Year-on-Year

CHAOJU EYE CARE released FY2024 Q3 earnings on March 26 (BJT), with actual revenue of 371.98 M HKD and EPS of 0.0446 HKD

CHAOJU EYE CARE released FY2024 9 Months Earnings on March 26 (BJT), actual revenue 1.164 B HKD, actual EPS 0.2588 HKD

CHAOJU EYE CARE released FY2024 annual earnings on March 26 (BJT), actual revenue 1.521 B HKD (forecast 1.641 B HKD), actual EPS 0.303 HKD (forecast 0.3821 HKD)

Chaoju Eye Care released FY2024 Q4 earnings on March 26 (BJT), actual revenue 357.01 M HKD, actual EPS 0.0428 HKD

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

02219

Chaoju Eye Care Holdings Ltd. has signed tenancy agreements for three premises with a five-year lease starting May 6, 2026. The agreements are classified as connected transactions due to the involvement of associates of a controlling shareholder's family. The right-of-use asset value exceeds 0.1% but is below the 5% threshold, thus requiring only reporting and announcement without independent shareholder approval. Chaoju Eye Care operates in the eye care sector in mainland China, providing clinical services and optical products.

Tip Ranks

Chaoju Eye Care Signs Connected Tenancy Deals for New Premises

300015

06622

China's leading private ophthalmology hospital chain Aier Eye plans to go public in Hong Kong to enhance brand awareness and broaden financing channels. Despite facing intense competition and price pressure, the company hopes to achieve growth through the expansion of the international ophthalmology market. Last year, its overseas ophthalmology clinic revenue grew by approximately 16%, double the overall revenue growth rate

BambooWorks

Aier

ZHAOKE OPHTH-B

Penghua SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

ChinaAMC CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Merchants CSI Biotechnology Theme ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

Bosera Hang Seng Health Care ETF(QDII)

E Fund CSI 300 Health Care ETF

ICBCCS SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

E Fund CSI Biotechnology Theme ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC CSI All Share Health Care Devices ETF

Guotai CSI Bio-medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

C-MER MEDICAL

Looking for overseas growth, Aier Eye seeks Hong Kong listing

Aier's board of directors has approved the relevant proposal for listing in Hong Kong, which requires approval from the shareholders' meeting and regulatory authorities. The company's profit is expected to decline by 8.88% in 2025, but the net profit in the first quarter of 2023 rebounded to 1.181 billion yuan, a year-on-year increase of 12.46%. Overseas business has become a new highlight, with expected overseas revenue reaching 3.057 billion yuan in 2025, accounting for 13.68% of total revenue. This listing aims to broaden international financing channels, and management stated that this move is to address valuation pressure and seek new narratives in the capital market

Aier plans to go public in Hong Kong. Can overseas expansion support the new valuation of "eye king"?

CHAOJU EYE CARE announced its full-year results for the year ending last December, with a revenue of RMB 1.36 billion, a year-on-year decrease of 3.2%. The net profit was RMB 183 million, a year-on-year decrease of 6%; earnings per share were RMB 0.26. The company declared a final dividend of HKD 0.2423, an increase from HKD 0.1193 in the same period last year. According to non-International Financial Reporting Standards, the adjusted net profit fell to nearly RMB 188 million, a decline of 7.3%. As of the end of last year, the number of ophthalmology hospitals and optometry centers operated by the group was 31 and 32, respectively, with the number of optometry centers increasing by 3 year-on-year

AASTOCKS

"Performance" CHAOJU EYE CARE's annual net profit is RMB 183 million, down 6%, with a final dividend of HKD 0.2423

Aier Eye Hospital is planning to go public in Hong Kong, and related preparations are underway. The company stated that significant information should be subject to official announcements. Insiders have confirmed that the news is true. If successful, Aier Eye Hospital will become the first ophthalmology hospital to be listed in both A-share and H-share markets

Wallstreetcn

Aier Eye Hospital plans to go public in Hong Kong and is indeed "ready to shoot."

Aier is considering an IPO in Hong Kong and is working with advisors to prepare for it, with the specific scale and timing still under discussion. The company has a market capitalization of approximately 96 billion RMB, and its stock price is close to a five-year low, having fallen about 26% in the past 12 months. Aier was founded in 2002, and its medical network covers Asia, Europe, and North America, with a total of 976 hospitals and clinics worldwide, including 807 in mainland China and 9 in Hong Kong

According to reports, Aier is considering listing in Hong Kong

Aier Eye Hospital is reportedly planning to go public on the Hong Kong Stock Exchange. (Bloomberg)

CHAOJU EYE CARE(02219.HK)